Developer docs
API playgroundTry for free, no card

Search company profiles

GenAssist

Full company profile

uuid000aj2p

Namestring
GenAssist
Legal namestring
GenAssist
Websiteurl
genassist.co
Company typeenum
Private
Founded yearint
2019
Descriptiontext

GenAssist is a St. Louis, Missouri-based pre-commercial medical-device company founded in 2019 that is developing MyoSponge, an implantable scaffold intended to regenerate functional skeletal muscle in patients suffering from Volumetric Muscle Loss (VML), a condition typically caused by severe orthopedic trauma such as car accidents or gunshot injuries in which dead tissue must be surgically debrided and the body's natural regeneration capacity is overwhelmed. The company targets hospitals and surgical centers performing orthopedic trauma and reconstructive surgery, with surgeons as the end users implanting the device at the point of injury.

MyoSponge is a biomaterial scaffold engineered to mimic the Basal Lamina, the native extracellular support structure that enables muscle-cell growth. The platform architecture allows patient-resident stem cells to migrate into the scaffold, proliferate, and mature into new muscle fibers, after which the scaffold gradually resorbs and is replaced by endogenous functional tissue. Core intellectual property is protected by granted US Patent 11,744,922 B2, and preclinical validation in an NSF SBIR-funded large-animal pig model of VML demonstrated a 46% improvement in muscle strength, 27% more muscle mass, and 75% more muscle fibers. Ongoing discovery work is conducted in partnership with Saint Louis University's Musculoskeletal Tissue Engineering Laboratory, where the technology was originally invented.

GenAssist operates a B2B enterprise sales motion that is currently in pre-revenue formation. Revenue, once generated, is expected to flow from one-time medical-device sales of MyoSponge to hospitals and surgical centers, priced via quotation-based B2B contracts. The company is pre-commercial, with awareness driven primarily by scientific publications, conference presence, and direct inquiries through its website. To date the company has raised modest non-dilutive and corporate capital (including a $295,000 NSF SBIR Phase I award in 2023, Arch Grants funding in 2025, and equity-style checks from Baxter, Endeavor Health, and Hologic) and operates with a 1–10 person founder-led team (CEO Joe Beggs, CTO Gabe Haas, Chief Discovery Officer Dr. Koyal Garg, and Senior Scientist Dr. Deepa Patil).

Short descriptiontext

GenAssist is a pre-commercial medical device company developing MyoSponge, an implantable biomaterial scaffold that regenerates skeletal muscle to treat Volumetric Muscle Loss in orthopedic trauma and reconstructive surgery patients at hospitals and surgical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomaterial implants, muscle regeneration scaffolds, orthopedic trauma devices, tissue engineering therapeutics, regenerative medicine implants
Industry2 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Regenerative Medicine Implants
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (MyoSponge)
TypeOne Time License
Description

Pre-commercial stage medical device company developing MyoSponge, an implantable scaffold for muscle regeneration. Revenue will be generated through direct sales of the medical device to healthcare providers (hospitals, surgical centers) for use in orthopedic trauma and reconstructive surgery procedures.

genassist.co
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GenAssist is developing MyoSponge, an implantable biomaterial scaffold designed to mimic the Basal Lamina and treat Volumetric Muscle Loss (VML) by supporting stem cell-driven regeneration of functional skeletal muscle in orthopedic trauma and reconstructive surgery patients. The product is targeted at healthcare providers (hospitals and surgical centers) and is currently in pre-commercial development, with the scaffold made from FDA-cleared materials and protected by US Patent 11,744,922 B2.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 46% muscle strength improvement
+2 more records
Product overview1 text field

GenAssist is developing biomaterials for orthopedic trauma and reconstructive surgery. The company is working on MyoSponge, the first commercialized technology designed to rebuild strength after Volumetric Muscle Loss (VML). MyoSponge is a muscle-regenerating implantable scaffold that serves as the core product offering, designed to be implanted by surgeons to structurally support damaged muscle tissue and facilitate regeneration of functional muscle.

Product and service1 record
1MyoSponge
CategoryRegenerative medicine / tissue-engineering implantable medical device
Description

A muscle-regenerating implantable scaffold designed to mimic the Basal Lamina (the native support structure that allows muscle cells to grow), targeting Volumetric Muscle Loss (VML) in orthopedic trauma and reconstructive surgery. The scaffold structurally supports damaged muscle tissue after necrotic tissue removal, enables patient stem cells to migrate, multiply, and mature into new muscle fibers, and then gradually resorbs and is replaced by functional muscle tissue. It is intended for implantation by orthopedic trauma and reconstructive surgeons at hospitals and surgical centers. The technology is protected by US Patent 11,744,922 B2.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic research partnership with Saint Louis University's Musculoskeletal Tissue Engineering Laboratory, led by Dr. Koyal Garg (Chief Discovery Officer). MyoSponge technology was invented at this academic institution, and the partnership provides ongoing scientific guidance, collaborative grant applications, and early-stage product research.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GenAssist

Regenerative Medicine Implantsgenassist.co

GenAssist is a pre-commercial medical device company developing MyoSponge, an implantable biomaterial scaffold that regenerates skeletal muscle to treat Volumetric Muscle Loss in orthopedic trauma and reconstructive surgery patients at hospitals and surgical centers.

What GenAssist does

GenAssist is a St. Louis, Missouri-based pre-commercial medical-device company founded in 2019 that is developing MyoSponge, an implantable scaffold intended to regenerate functional skeletal muscle in patients suffering from Volumetric Muscle Loss (VML), a condition typically caused by severe orthopedic trauma such as car accidents or gunshot injuries in which dead tissue must be surgically debrided and the body's natural regeneration capacity is overwhelmed. The company targets hospitals and surgical centers performing orthopedic trauma and reconstructive surgery, with surgeons as the end users implanting the device at the point of injury.

MyoSponge is a biomaterial scaffold engineered to mimic the Basal Lamina, the native extracellular support structure that enables muscle-cell growth. The platform architecture allows patient-resident stem cells to migrate into the scaffold, proliferate, and mature into new muscle fibers, after which the scaffold gradually resorbs and is replaced by endogenous functional tissue. Core intellectual property is protected by granted US Patent 11,744,922 B2, and preclinical validation in an NSF SBIR-funded large-animal pig model of VML demonstrated a 46% improvement in muscle strength, 27% more muscle mass, and 75% more muscle fibers. Ongoing discovery work is conducted in partnership with Saint Louis University's Musculoskeletal Tissue Engineering Laboratory, where the technology was originally invented.

GenAssist operates a B2B enterprise sales motion that is currently in pre-revenue formation. Revenue, once generated, is expected to flow from one-time medical-device sales of MyoSponge to hospitals and surgical centers, priced via quotation-based B2B contracts. The company is pre-commercial, with awareness driven primarily by scientific publications, conference presence, and direct inquiries through its website. To date the company has raised modest non-dilutive and corporate capital (including a $295,000 NSF SBIR Phase I award in 2023, Arch Grants funding in 2025, and equity-style checks from Baxter, Endeavor Health, and Hologic) and operates with a 1–10 person founder-led team (CEO Joe Beggs, CTO Gabe Haas, Chief Discovery Officer Dr. Koyal Garg, and Senior Scientist Dr. Deepa Patil).

GenAssist firmographics

Firmographics
Name
GenAssist
Legal name
GenAssist
Website
https://genassist.co
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
GenAssist is a pre-commercial medical device company developing MyoSponge, an implantable biomaterial scaffold that regenerates skeletal muscle to treat Volumetric Muscle Loss in orthopedic trauma and reconstructive surgery patients at hospitals and surgical centers.
Ownership category
akta.pro rank

GenAssist industry classification

Industry
Product category
Regenerative Medicine Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Biomaterial implants
  • Muscle regeneration scaffolds
  • Orthopedic trauma devices
  • Tissue engineering therapeutics
  • Regenerative medicine implants

Where GenAssist is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GenAssist business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales (MyoSponge): Pre-commercial stage medical device company developing MyoSponge, an implantable scaffold for muscle regeneration. Revenue will be generated through direct sales of the medical device to healthcare providers (hospitals, surgical centers) for use in orthopedic trauma and reconstructive surgery procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

GenAssist product offering

Product offering

Core offering

GenAssist is developing MyoSponge, an implantable biomaterial scaffold designed to mimic the Basal Lamina and treat Volumetric Muscle Loss (VML) by supporting stem cell-driven regeneration of functional skeletal muscle in orthopedic trauma and reconstructive surgery patients. The product is targeted at healthcare providers (hospitals and surgical centers) and is currently in pre-commercial development, with the scaffold made from FDA-cleared materials and protected by US Patent 11,744,922 B2.

Product overview

GenAssist is developing biomaterials for orthopedic trauma and reconstructive surgery. The company is working on MyoSponge, the first commercialized technology designed to rebuild strength after Volumetric Muscle Loss (VML). MyoSponge is a muscle-regenerating implantable scaffold that serves as the core product offering, designed to be implanted by surgeons to structurally support damaged muscle tissue and facilitate regeneration of functional muscle.

Differentiator

Problem solved

Functional benefit

Products and services

  • MyoSponge A muscle-regenerating implantable scaffold designed to mimic the Basal Lamina (the native support structure that allows muscle cells to grow), targeting Volumetric Muscle Loss (VML) in orthopedic trauma and reconstructive surgery. The scaffold structurally supports damaged muscle tissue after necrotic tissue removal, enables patient stem cells to migrate, multiply, and mature into new muscle fibers, and then gradually resorbs and is replaced by functional muscle tissue. It is intended for implantation by orthopedic trauma and reconstructive surgeons at hospitals and surgical centers. The technology is protected by US Patent 11,744,922 B2.

Quantifiable outcome

  • 46% muscle strength improvement
  • +2 more outcomes

Companies that use GenAssist

Customer profile

Segments1 record

Ideal customer profiles1 record

GenAssist technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

GenAssist partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Saint Louis UniversitycoreStrategic or Co-development PartnerStrategic research partnership with Saint Louis University's Musculoskeletal Tissue Engineering Laboratory, led by Dr. Koyal Garg (Chief Discovery Officer). MyoSponge technology was invented at this academic institution, and the partnership provides ongoing scientific guidance, collaborative grant applications, and early-stage product research.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

GenAssist competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

GenAssist social profiles

Digital presence

GenAssist financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GenAssist leadership team

Management profile

Number of profiles

Profiles4 records

GenAssist funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GenAssist M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenAssist

What does GenAssist do?

GenAssist is developing MyoSponge, an implantable biomaterial scaffold designed to mimic the Basal Lamina and treat Volumetric Muscle Loss (VML) by supporting stem cell-driven regeneration of functional skeletal muscle in orthopedic trauma and reconstructive surgery patients. The product is targeted at healthcare providers (hospitals and surgical centers) and is currently in pre-commercial development, with the scaffold made from FDA-cleared materials and protected by US Patent 11,744,922 B2.

Is GenAssist a public or private company?

GenAssist is a private company. It is classified as venture growth investor backed and is currently operating.

When was GenAssist founded?

GenAssist was founded in 2019. It employs 1 to 10 people.

Where is GenAssist based?

GenAssist is headquartered in St Louis, United States, in the North America region.

How does GenAssist make money?

One revenue line is on record: medical Device Sales (MyoSponge).

Does GenAssist have an API?

No public API is recorded for GenAssist.

What industry is GenAssist in?

GenAssist's product category is Regenerative Medicine Implants. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals